Phaseline

Companies › Trogenix

Trogenix: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TGX-007
AAV-mediated dual-payload gene therapy delivering HSV-tk and IL-12 for tumor cell killing
HSV-TK, IL12Phase 1Glioblastoma (GBM)Mar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07346144TGX-007Phase 1Glioblastoma (GBM)OncologyMar 2030

Targets

HSV-TK (1) IL12 (1)

Companies with the same targets

Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.